A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer

References

• BenceAKAndersonEBHalepotaMAPhase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthly subjectsInvest New Drugs200523394915528979
   PubMed Web of Science ®Google Scholar
• BennasrouneAGardinAAunisDTyrosine kinase receptors as attractive targets of cancer therapyCrit Rev Oncol Hematol200450233815094157
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHPegramMDetermining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancerProc Am Soc Clin Oncol2005233004
   Web of Science ®Google Scholar
• BurrisHADual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinibThe Oncologist2004910515163842
   PubMed Web of Science ®Google Scholar
• BurrisHAIIIHurwitzHIDeesECPhase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible, Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases in Heavily Pretreated Patients With Metastatic CarcinomasJ Clin Oncol20052353051315955900
   PubMed Web of Science ®Google Scholar
• CoxMCDanTDSwainSMEmerging drugs to replace current leaders in first-line therapy for breast cancerExpert Opinion on Emerging Drugs20061148950116939387
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative GEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet20053651687717
   PubMed Web of Science ®Google Scholar
• El-RayesBFLorussoPMTargeting the epidermal growth factor receptorBr J Cancer2004914182415238978
   PubMed Web of Science ®Google Scholar
• EngelJEckelRAydemirUDeterminants and prognosis of locoregional and distant progression in breast cancerInternational Journal of Radiation Oncology, Biology, Physics200355118695
   PubMed Web of Science ®Google Scholar
• FieldsALARinaldiDAHendersonCAAn open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancerProc Am Soc Clin Oncol2005233583
   Google Scholar
• FlahertyKTBroseMSHer-2 targeted therapy: beyond breast cancer and trastuzumabCurrent Oncology Reports2006890516507217
   PubMedGoogle Scholar
• GeyerCECameronDWLindquistSA phase III randomized, open-label international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151)2006The 42nd Annual Meeting of the American Society of Clinical OncologyAtlanta, GA
   Google Scholar
• GlaxosmithklineGlaxoSmithKline reports positive new data on Tykerb® (lapatinib ditosylate)2006 http://www.gsk.com/controllerservlet?appId=4&pageId=402&newsid=843
   Google Scholar
• GomezHLChavezMADovalDCA phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancerProc Am Soc Clin Oncol2005233046
   Google Scholar
• Graus-PortaDBeerliRRDalyJMErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingEMBO Journal1997161647559130710
   PubMed Web of Science ®Google Scholar
• HackelPOZwickEPrenzelNEpidermal growth factor receptors: critical mediators of multiple receptor pathwaysCurr Opin Cell Biol199911184910209149
   PubMed Web of Science ®Google Scholar
• HerendeenJMSmithDASteadAAn open-label, fixed-sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepineJournal of Clinical Oncology2004223081
   Web of Science ®Google Scholar
• JemalASiegelRWardECancer Statistics20065610630
   Web of Science ®Google Scholar
• JohnstonSRLearyALapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancerDrugs Today2006424415316894399
   PubMed Web of Science ®Google Scholar
• JonesSFBurrisHAYardleyDA[1069] Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel2004San Antonio Breast Cancer SymposiumSan Antonio, TX
   Google Scholar
• KarunagaranDTzaharEBeerliRRErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerEMBO Journal199615254648617201
   PubMed Web of Science ®Google Scholar
• KingCRBorrelloIBellotFEgf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3EMBO Journal198871647512901952
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer CellsCancer Res20066616303916452222
   PubMed Web of Science ®Google Scholar
• LangerCJEmerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCInt J Radiat Oncol Biol Phys200458991100214967461
   PubMed Web of Science ®Google Scholar
• LevineMNWhelanTAdjuvant chemotherapy for breast cancer – 30 years laterN Engl J Med20063551920217079767
   PubMed Web of Science ®Google Scholar
• LinNUCareyLALiuMCPhase II trial of lapatinib for brain metastasis in patients with HER2+ breast cancerJournal of Clinical Oncology200624503
   Google Scholar
• LinNUWinerEPSmall molecule tyrosine kinase inhibitorsBreast Cancer Res200462041015318926
   PubMed Web of Science ®Google Scholar
• McphersonKSteelCMDixonJMABC of breast diseases: Breast cancer – epidemiology, risk factors, and genetics20003216248
   Google Scholar
• MoyBGossPELapatinib: Current status and future directions in breast cancerOncologist20061110475717110623
   PubMed Web of Science ®Google Scholar
• NabholtzJ-MGligorovJThe role of taxanes in the treatment of breast cancer20056107394
   Google Scholar
• NahtaREstevaFJHER-2 targeted therapy: Lessons learned and future directionsClin Cancer Res2003950788414613984
   PubMed Web of Science ®Google Scholar
• NelsonMHDolderCRLapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors (February)Ann Pharmacother2006 aph.1G387
   Web of Science ®Google Scholar
• NgMCunninghamDCetuximab (Erbitux) – an emerging targeted therapy for epidermal growth factor receptor-expressing tumorsInt J Clin Pract200458970615587777
   PubMed Web of Science ®Google Scholar
• PeckSRLapatinib, a dual ErbB-1/ErbB-2 kinase inhibitor, in the treatment of HER2-overexpressing local advanced and metastatic breast cancerClinical Breast Cancer200672247
   Web of Science ®Google Scholar
• PegramMDPietrasRBajamondeATargeted Therapy: Wave of the FutureJ Clin Oncol20052317768115755985
   PubMed Web of Science ®Google Scholar
• PerezEAByrneJAHammondIWResults of an analysis of cardiac function in 2,812 patients treated with lapatinibJournal of Clinical Oncology200624583
   Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-PositiveBreast Cancer2005353167384
   Google Scholar
• Ruiz-PalaciosGMPerez-SchaelIVelazquezFRSafety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisN Engl J Med2006354112216394298
   PubMed Web of Science ®Google Scholar
• RusnakDWAffleckKCockerillSGThe characterization of novel dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancerCancer Res2001a61719620311585755
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in VivoMolecular Cancer Therapeutics2001b1859412467226
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene198723517782
   Google Scholar
• SlamonDJGodolphinWStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience1989244707122470152
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013447839211248153
   PubMed Web of Science ®Google Scholar
• SmithDABowenCJHerendeenJMAn open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazoleJournal of Clinical Oncology2004223071
   Web of Science ®Google Scholar
• SpectorNLBlackwellKLHurleyJEGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of responseJournal of Clinical Oncology200624502
   Web of Science ®Google Scholar
• SpectorNLXiaWBurrisHIIIStudy of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesJ Clin Oncol20052325021215684311
   PubMed Web of Science ®Google Scholar
• StornioloAMBurrisHPegramMA phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimenProc Am Soc Clin Oncol200523559
   PubMed Web of Science ®Google Scholar
• TibesRTrentJKurzrockRTyrosine kinase inhibitors and the dawn of molecular cancer therapeuticsAnnu Rev Pharmacol Toxicol2005453578415822181
   PubMed Web of Science ®Google Scholar
• UenoNTBuzdarAUSingletarySECombined-modality treatment of inflammatory breast cancer carcinoma: twenty years of experience at M.D Anderson Cancer CenterCancer Chemotherapy and Pharmacology19974032199225950
   PubMed Web of Science ®Google Scholar
• VersolaMBurrisHAJonesSClinical activity of GW572016 in EGF10003 in patients with solid tumors (abstract)J Clin Oncol (Meeting Abstracts)2004223047
   Web of Science ®Google Scholar
• WilkinsonGRDrug metabolism and variability among patients in drug responseN Engl J Med200535222112115917386
   PubMed Web of Science ®Google Scholar
• WulfingCMachielsJPRichelDA single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tractProc Am Soc Clin Oncol2005234594
   Web of Science ®Google Scholar
• XiaWBisiJStrumJRegulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancersCancer Res2006661640716452223
   PubMed Web of Science ®Google Scholar
• XiaWGerardCMLiuLCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells200524621321
   Google Scholar
• XiaWLiuL-HHoPTruncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene2004236465314737100
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene20022162556312214266
   PubMed Web of Science ®Google Scholar
• ZhouHKimY-SPeletierAEffects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpressing breast cancer cell line proliferation radiosensitization and resistanceInt J Radiat Oncol Biol Phys2004583445214751502
   PubMed Web of Science ®Google Scholar
• ZhouSChanSYGohBCMechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugsClin Pharmacokinet20054427930415762770
   PubMed Web of Science ®Google Scholar